COVID-19 and MDR-Game Changers in Medical Translation

摘要

This is also true of the language industry. Working remotely and its implications - so omnipresent in many media these days - hasn't really been much of a novelty for many LSPs, which have been digitally connecting internal and external project teams from different parts of the world for years already. Some industry sectors, however, had to adapt to changes in their usual environment which are, at least in part, likely to last.One of these sectors is translation for certain medical products. It would be unfair to describe this as entirely static before the outbreak of the pandemic. However, its stakeholders now certainly have to deal with a few challenges less known to them before, specifically in connection with the atypical speed at which tests, vaccines, and medicines are developed and eventually marketed. With a specialist term like "rolling review" - a process under which public health authorities like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) start evaluation of preliminary laboratory and clinical data for a medical product as it becomes available from studies that are still ongoing, instead of requiring it to be complete at the start of the review process - becoming almost commonplace, a kind of "agile" approach has taken hold in a field where it was formerly viewed with mistrust.